PDK1 and metabolic disease: In conclusion, we confirmed that PDK1 inhibitor exacerbated the development of OA, and the underlying mechanism might be related to the glucose metabolism disorder, which leads to an imbalance of anabolic and catabolic processes of chondrocytes and accelerates inflammation.